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Abstract
Eumycetoma is a debilitating chronic inflammatory fungal infection that exists worldwide but
it is endemic in many tropical and subtropical regions. The major causative organism is the
fungusMadurella mycetomatis. The current treatment of eumycetoma is suboptimal and
characterized by low cure rate and high recurrence rates. Hence, an alternative therapy is
needed to address this. Here we determined the antifungal activity of seven Sudanese me-
dicinal plant species againstMadurella mycetomatis. Of these, only three species; Boswel-
lia papyrifera, Acacia nubica and Nigella sativa, showed some antifungal activity againstM.
mycetomatis and were further studied. Crude methanol, hexane and defatted methanol ex-
tracts of these species were tested for their antifungal activity. B. papyrifera had the highest
antifungal activity (MIC50 of 1 ug/ml) and it was further fractionated. The crude methanol
and the soluble ethyl acetate fractions of B. papyrifera showed some antifungal activity. The
Gas-Liquid-Chromatography hybrid Mass-Spectrophotometer analysis of these two frac-
tions showed the existence of beta-amyrin, beta-amyrone, beta-Sitosterol and stigmatriene.
Stigmatriene had the best antifungal activity, compared to other three phytoconstituents,
with an MIC-50 of 32 μg/ml. Although the antifungal activity of the identified phytoconstitu-
ents was only limited, the antifungal activity of the complete extracts is more promising, indi-
cating synergism. Furthermore these plant extracts are also known to have anti-
inflammatory activity and can stimulate wound-healing; characteristics which might also be
of great value in the development of novel therapeutic drugs for this chronic inflammatory
disease. Therefore further exploration of these plant species in the treatment of mycetoma
is encouraging.
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Author Summary
This study was an attempt to discover new safe therapeutic modalities of natural origin for
the treatment eumycetoma. The methanolic extracts of seven selected local plants were
screened for their antifungal activity. All seven plant extracts were able to inhibitMadur-
ella mycetomatis growth at a concentration of 50 μg/ml or less. Three plant species out of
the seven managed to inhibit the growth ofMadurella mycetomatis at a concentration as
low as 781 μg/ml; these were: Boswellia papyrifera, Acacia nubica and Nigella sativa. Fur-
ther analysis of B. Papyrifera, using Gas-Liquid-Chromatography hybrid Mass-Spectro-
photometer (GC-MS); showed the occurrence of four phytoconstituents, triterpenoid in
nature and these were Beta-amyrin, Beta-amyrone, Beta-Sitosterol and Stigmatriene. Stig-
matriene was the best to show anti-mycetoma activity at an MIC equal to 32 μg/ml. This
MIC is much higher than the MIC of the whole extract (8 μg/ml), indicating that other
compounds or a combination of compounds has a better ability to inhibitM.mycetomatis
growth. These results are promising and further detailed studies are highly recommended.
Introduction
Eumycetoma is a neglected tropical chronic subcutaneous inflammatory disease commonly
caused byMadurella mycetomatis. It is characterised by a painless subcutaneous mass, multiple
discharging sinuses and discharge that usually contains grains [1, 2]. The infection usually pro-
gresses to involve the skin, deep structures and ultimately the bone leading to massive deformi-
ties, distortions and disabilities [3, 4, 5].
Eumycetoma is reported worldwide but is endemic in tropical and subtropical regions, in
what is known as the mycetoma belt and stretches between 15° South and 30° North of the
equator [6]. Young active adults are mostly affected [7]. Mycetoma has several adverse effects
on patients, communities and health authorities [8, 9].
The available eumycetoma treatment is a combination of massive surgical excisions and
long term antifungal therapy [10, 11]. The therapeutic response to this regimen is suboptimal,
characterized by low cure and high recurrence rates [12]. Currently ketoconazole and itracona-
zole are the antifungal drugs of choice. In Sudan, ketoconazole has been the drug of choice. Un-
fortunately, this drug can cause serious side effects such as hepatic toxicity, and is therefore in
2013 suspended for use by the US Food and Drug Administration and the European Medicines
Agency. Furthermore, the drug appeared also expensive for people living in endemic areas,
costing as much as a third of their monthly income [13,14]. Officially ketoconazole has now
been replaced by itraconazole. Itraconazole is less toxic but unfortunately also appears to be
less effective in mycetoma treatment. It creates a tough fibrous tissue around the mycetoma le-
sions which facilitate their surgical excision [14]. It is interesting to note in these lesions the or-
ganisms are commonly present and viable in culture which indicates that, these antifungal
drugs are simply localizing the infection and not eradicating it [14]. This perhaps is quite as-
tonishing as many in vitro studies showed thatM.mycetomatis is inhibited in growth at low
concentrations of these therapeutic agents [15, 16, 17, 18]. But this was explained by host fac-
tors and/ or factors from the causative agent such as the grain melanin particularly DHN-mela-
nin which proved to be responsible for this observation [19, 20].
Therefore there is a need for a better and more effective therapy for eumycetoma. An unex-
plored resource of novel therapeutic agents is the locally growing herbs which are often used in
traditional medicine. A recently study conducted at the Mycetoma Research Centre, Sudan
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showed that, 42.4% of the studied population used herbal medicine for the treatment of eumy-
cetoma at some stage of their illness with a complication rate of 29.3% [21].
Although such a large portion of the mycetoma patients use herbal medicine, there is rela-
tively few information on the antifungal activity of these herbs. We therefore set out this study,
to determine the antifungal activity of seven Sudanese plant species used in these local herbal
treatments againstM.mycetomatis in the hope to develop an alternative novel treatment for
mycetoma in the future.
Materials and Methods
Plant species used
In this study seven Sudanese plants species were tested for antifungal activity against 13 inde-
pendent clinicalM.mycetomatis isolates. The parts tested were gum resin of Boswellia papyri-
fera of the family Burseraceae, root bark of Acacia nubica of theMimosaceae family, seeds and
fruits of Nigella sativa of the family Renunculaceae, flower buds of Eugenia caryophyllus of the
familyMyrtaceae, rhizome of Zingiber officinalis of the family Zingiberaceae, stem peel of Cin-
namon verum of the family Lauraceae and fruits of Piper nigrum of the family Piperaceae.
Preparations of the plant extracts
The plant extracts were prepared from dried coarsely powdered samples macerated separately
in conical flasks with methanol over seven days at room temperature. Following filtration,
crude methanolic extracts were dried under vacuum using a rotatory evaporator at 60°C. The
extracts were dissolved separately in 70% alcohol and subjected to liquid-liquid partitioning
using hexane to obtain three products: a crude methanol extract, a hexane fraction and a defat-
ted methanol fraction as described previously. [22, 23, 24]
Identification of potential antifungal components in the crude extracts of
Boswellia papyrifera
To determine which components in these extracts were responsible for the antifungal activity
of Boswellia papyrifera, methanol extracts were fractionated using a separating funnel succes-
sively with hexane and ethyl acetate to produce four fractions: an exhausted methanol fraction,
a hexane fraction, a crude methanol extract and an ethyl acetate fraction. The fraction in which
the antifungal activity was detected was further characterized by Gas liquid Chromatography
hybrid Mass spectrophotometry (GC-MS) analysis.
For this extracts were dissolved in ethyl acetate, and one μl injections were made in split
mode at injection temperature 280°C. Initial temperature was 80°C, then increased at 10°C/
min; compounds were identified by comparison of their mass spectra with those from the
NIST’98 mass spectral database. The identified triterpenoid phytoconstituents were Beta-
amyrin, Beta-amyrone, Beta-sitosterol and Stigmatriene. To test the antifungal activities of
these phytoconstituents, the pure compounds were purchased by Sigma.
Determining the in vitro activities of the different extracts and
compounds againstM.mycetomatis
The broth microdilution method was used to determine the crude methanol extract, hexane
fraction, defatted methanol fraction, crude methanol fraction, exhausted soluble methanol
fraction, soluble hexane fraction, soluble ethyl acetate fraction, Beta-amyrin, Beta-amyrone,
Beta-sitosterol and Stigmatriene antifungal activity against clinicalM.mycetomatis isolates
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Each of theM.mycetomatis isolates was identified to the species level by sequencing the ITS
region [15–18]. The procedure started with the culturing ofM.mycetomatis for 10 days at 37°
in RPMI-1640 medium supplemented with L-glutamine (0.3g/L) and 6 ml MOPS of 0.165 M.
The resulting mycelia were harvested by 5 minutes centrifugation at 2158 g and washed with
normal saline. The mycelia were homogenized by sonicating for 20 seconds at 28 micron,
using a sonicator (Mesonix-CEMODEL3510E-MT-Mexico S/Nqpko40517794). The final inoc-
ulum was prepared by adjusting the homogenized fungal suspension to obtain an optical trans-
mission of 70% at 660 nm. Of this suspension 100 microliters were transferred into a
microtitration plate. To each well 2 μl of a two-fold dilution of each extract in DMSO was
added. The microtitration plate was incubated for 7 days at 37°C before the endpoints were
read. The MIC was determined to be the first well in which no growth was visible. Biological as-
says were compared to negative, positive; inoculum and solvent controls. As a comparator
agent, ketoconazole was applied in all plates. All assays were performed in triplicate. To facili-
tate the endpoint reading, XTT was added after incubation as described elsewhere [22].
Results
The extracts from Boswellia papyrifera appear to have the most potent
antifungal activity againstM.mycetomatis
In order to determine if seven of the locally used medicinal plants have any antifungal activity
againstM.mycetomatis, crude methanol extracts of E. caryophillus, C. verum, P. nigrum, Z. offi-
cinalis, A. nubica, N. sativa and B. papyrifera were prepared (Table 1). All the studied methanol
extracts were able to inhibitM.mycetomatis growth at a concentration of 50 μg/ml. Three of
these extracts had a more potent antifungal activity and these were A. nubica, N. sativa and B.
papyrifera. They inhibitedM.mycetomatis growth at a concentration as low as 1 μg/ml
(Table 1)]. Hence, these three plant species were selected for further study. Crude methanol ex-
tracts, hexane extracts and the defatted methanol extracts were prepared from these plant spe-
cies and their antifungal activities were determined for the clinicalM.mycetomatis isolates.
Low MICs were found for all three extracts, with MIC-50s ranging from 1 μg/ml to 4 μg/ml
(Table 1).
The most potent antifungal activity was documented in the crude methanol extracts of B.
papyrifera (Table 1). The crude methanol fraction of B. papyrifera was further fractionated into
four different fractions: a crude methanol fraction, an exhausted soluble methanol fraction, a
soluble hexane fraction and a soluble ethyl acetate fraction to determine in which of these frac-
tions the antifungal activity was present. TheM.mycetomatis growth was inhibited only by the
crude methanol fraction and the soluble ethyl acetate fraction, (Table 1).
To determine the exact nature of the antifungal compounds, GC-MS analyses were per-
formed on the crude methanol extract and the soluble ethyl acetate fractions. It appeared that
in both extracts high amounts of tetracyclic and pentacyclic triterpenoid compounds were
present. These compounds were identified as: Beta-amyrin, Beta-amyrone, Beta-sitosterol and
Stigmatriene based on the comparison of their retention times and masses with those from the
NIST’98 mass spectral database (Table 2). Strikingly, only Beta-amyrone and Stigmatriene
were present in both extracts in relatively high concentrations.
Since in the active fractions of the B. papyrifera extracts; high concentrations of Beta-
amyrin, Beta amyrone, Beta-sitosterol and Stigmatriene were found, it was our plan to deter-
mine if any of these phytoconstituents can exhibit antifungal activity againstM.mycetomatis.
Findings revealed that, Beta-amyrin, beta-amyrone and beta-sitosterol only had limited activity
againstM.mycetomatis (Table 3). Only four isolates were inhibited by lower concentrations of
beta-amyrin and beta-amyrone and only two for beta-sitosterol. The other isolates were not
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inhibited by these compounds at the highest concentration tested. For stigmatriene most iso-
lates were inhibited at lower concentrations and only four isolates were not inhibited at all. But
even for stigmatriene the overall MICs obtained were relatively high, compared to the
whole extract.
Discussion
In many centers extensive eumycetoma lesions are still treated with a combination of massive
surgical excisions (or amputation) and prolonged antifungal therapy [10,11]. These treatment
modalities are based on personal clinical experience and a few case reports rather than con-
trolled clinical trials [10]. The treatment outcome is appalling and dreadful characterized by
low cure rate, high recurrence and complications rates [12]. Eumycetoma patients characteris-
tically have high drug incompliance and follow-up dropout rates due to the gross patients’ dis-
satisfaction with the current treatment [12]. Hence, there is a pressing need for novel
therapeutic approaches.
Table 1. In vitro antifungal activities of several extracts of seven locally plant species against 13M. mycetomatis isolates.
MIC 501 (range)
in μg/ml
Plant species Crude
methanol
extract
Hexane
extract
Defatted
methanol
extract
Crude
methanol
fraction
Exhausted soluble
methanol fraction
Souble
hexane
fraction
Soluble ethyl
acetate fraction
Eugenia
caryophillus
50 (ND2) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND)
Cinnamum
verum
25 (ND) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND)
Piper nigrum 25 (ND) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND)
Zingiber
ofﬁcinalis
12.5 (ND) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND) ND (ND)
Acacia nubica 1 (0.5–128) 2 (0.25–
128)
4 (0.5–128) ND (ND) ND (ND) ND (ND) ND (ND)
Nigella sativa 1 (0.5–128) 2 (0.25–
128)
4 (0.25–128) ND (ND) ND (ND) ND (ND) ND (ND)
Boswellia
papyrifera
1 (0.5–128) 1 (0.25–
128)
2 (0.25–128) 8 (8) 128 (128) 128 (128) 8 (8)
Ketoconazole 0.125 (0.03–
0.25)
1Minimal inhibitory concentrations (MIC) at which at least 50% of the M. mycetomatis isolates was inhibited (MIC50).
2ND: not done.
doi:10.1371/journal.pntd.0003488.t001
Table 2. GC-MS analysis presenting triterpenes identiﬁed by GC/MS in Boswellia papyrifera extracts.
Fraction Retention time % area Base peak Molecular weigth Identiﬁcation of compound
Crude methanol 20.614 18.24 218 424 beta-amyrone
20.757 0.48 392 410 Stigmatriene
22.09 20.17 218 426 beta-amyrin
soluble ethyl acetate 20.614 12.46 218 424 beta-amyrone
20.757 72.41 392 410 Stigmatriene
21.752 2.53 129 486 beta-sitosterol
doi:10.1371/journal.pntd.0003488.t002
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Although, plants have been traditionally used as local remedies against various infectious
diseases, their activity against mycetoma causative agents have been hardly studied. Only one
report appeared to literature which studied the in vitro activity of plant extracts such as artemi-
sinin and tea tree oil onM.mycetomatis. In that study it was demonstrated that that artemisnin
was not active againstM.mycetomatis, but tea tree oil did inhibit its growth at concentrations
below 0.25% (v/v), which was comparable to other fungal species [18,25]. Tea tree oil is a prod-
uct not available in the Sudan and hence we tested other local plant species with reported
antifungal activities.
Seven locally accessible medicinal plant species were selected and tested for activity against
eumycetoma. The study demonstrated variable antifungal activity againstM.mycetomatis, but
the plants Boswellia papyrifera, Acacia nubica and Nigella sativa appeared to be the most po-
tent ones. The fact that, extracts of B. papyrifera showed antifungal activity againstM.myceto-
matis is not surprising since the antibacterial and antifungal activities of B. carterii, B. neglecta,
B. sacra, B. thurifera, B. frereana, B. papyrifera, B. socrotrana and B. papyrifera are widely re-
ported [26][27]. Furthermore, Boswellia essential oils were not only able to inhibit the fungal
growth, they were also able to inhibit germ tube formation in C. albicans [26–28] and to pre-
vent Candida albicans biofilm formation [26–28–29–30], both important for pathogenicity. Es-
pecially the latter feature could be important in mycetoma too. The Candida biofilm is
composed of Candida cells immobilized in matrix, known to consist mainly of carbohydrates
and small amounts of protein, hexosamine, phosphorus and uronic acid [29–30]. Likewise, the
M.mycetomatis grain also consists of fungal cells entrapped in a matrix like material called ce-
ment [28–29–30]. The composition of the cement differs from that of the Candida biofilm in
that it is carbohydrate poor, and rich in fat and proteins [29–30], but like the Candida biofilm
it is highly resistant against antifungal agents. Therefore any compound able to inhibit Candida
biofilm formation or even to disrupt this biofilm might be able to do the same with the cement
material of theM.mycetomatis grain.
Next to the reported B. papyrifera antifungal activities, Boswellia species also have known to
possess bioactive molecules which are active in inflammatory and malignant diseases and in
wound healing [31–32]. The compounds responsible for this anti-inflammatory reaction are
thought to be boswellic acids and quercetin [32–34]. From in vitro studies and animal models
it was learned that, boswellic acids inhibit the synthesis of pro-inflammatory enzymes, 5-lipox-
ygenase and leukotriene B and thereby prevent bronchoconstriction, chemotaxis, and decrease
vascular permeability [32–33]. Furthermore, the anti-inflammatory activity of mixture of bos-
wellic acids produced a 25–46% inhibition of paw oedema in rats and mice [35], which could
be important in the mycetoma pathology since large swellings are also present in this disease.
Furthermore, since a large inflammation zone is present surrounding the grain (33), any essen-
tial oil which also has anti-inflammatory properties will have some effect on the pathogenesis
of this disease.
Table 3. In vitro antifungal activities identiﬁed of triterpenoidal compounds from the B. papyrifera
extracts against 12M. mycetomatis isolates.
Compound MIC50 (range) in μg/ml
beta-amyrin >256 (0.5->256)
beta-amyrone >128 (0.25 - >128)
beta-sitosterol >128 (0.125 - >128)
stigmatriene 32 (0.125->128)
doi:10.1371/journal.pntd.0003488.t003
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Furthermore, although the Boswellia papyrifera extracts in overall appear to be effective and
safe to administer [37–38–39–40], identification of the active phytoconstituents is still manda-
tory. This is important to decrease the probabilities of expected adverse effects and to dramati-
cally increase the prospective extract efficacy when the isolated compounds are used
as medication.
The study showed that, the overall the purified stigmatriene MICs were much less than for
the crude extracts. This indicates that either stigmatriene is not the only antifungal compound
present or that the different components present in the crude extracts might act synergistically.
Indeed, in other studies several other compounds were found to be the active ingredient of Bos-
wellia resins [26,27,28]. Based on these observations, more studies are needed on the antifungal
mechanism of these extracts before they can be developed as potential new antifungal agents
for the treatment of eumycetoma.
In conclusion, the present study showed that, B. papyrifera, A. nubica and N. sativa have
some in vitro antifungal activity againstM.mycetomatis, and the most potent were the B.
papyrifera extracts. Although the antifungal activity of the identified compounds in these ex-
tracts was only limited, and the antifungal activity of the complete extracts was more promis-
ing. Furthermore these plant extracts are also known to have anti-inflammatory activity and
stimulate wound-healing and that can be helpful in managing patients with mycetoma.
Author Contributions
Conceived and designed the experiments: HE AFWK EMAWvdS. Performed the experi-
ments: HE AFWK EMAWvdS. Analyzed the data: HE AFWK EMAWvdS. Contributed re-
agents/materials/analysis tools: HE AFWK EMAWvdS. Wrote the paper: HE AFWK EMA
WvdS.
References
1. Fahal AH. (2013) Mycetoma in Williams, Bulstrode, O’Connell, Bailey and Love’s Short Practice of Sur-
gery 26E: 26th Edition, Oxford University Press, pp 64–68
2. Fahal AH. (2011) Mycetoma in Richard, Guerrant, Walker, Peter, Tropical Infectious Diseases: Princi-
ples, Pathogens and Practice. Third edition, Elsevier Publisher, chapter 83, pp. 565–568. doi: 10.
1007/s13197-011-0525-7 PMID: 24587533
3. Fahal AH. (2011) Mycetoma. Review article, KhartoumMed J. 4(1): 514–523.
4. Fahal AH, Hassan MA (1992) Mycetoma. Br J Surg 79(11): 1138–1141. PMID: 1467883
5. Fahal AH (2004) Mycetoma thorn on the flesh. Review article. Trans R Soc Trop Med Hyg 98(1):3–11.
PMID: 14702833
6. Fahal AH, van de SandyWW (2012) The Epidemiology of mycetoma. Curr Fungal Infect Rep 6 (4):
320–326.
7. Van Belkum A, Fahal A, van de SandeWW (2013) Mycetoma caused by Madurella mycetomatis: a
completely neglected medico-social dilemma. Adv Exp Med Biol 764:179–189. PMID: 23654067
8. Ahmed AA, van de SandeWW, Fahal AH, Bakker-Woudenberg I, Verbrugh H, et al. (2007) Manage-
ment of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin
Infect Dis 20(2):146–51. PMID: 17496572
9. Ahmed AO, van LeeuwenW, Fahal A, van de SandeWW, Verbrugh H, et al. (2004) Mycetoma caused
by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 4(9):566–74 PMID:
15336224
10. Fahal AH, Elkhawad AO. (2013) Treating Mycetoma: Guidelines for Best Practice. Expert Rev Derma-
tol 8(3): 301–307.
11. Fahal AH. (2010) Management of mycetoma. Expert Rev Dermatol 5(1), 87–93.
12. Zein HAM, Fahal AH, Mahgoub ES, EL Hassan T, Abdel Rahman ME. (2012) The Predictors of Cure,
Amputation & Follow-up dropout among Mycetoma Patients as seen at The Mycetoma Research Cen-
tre, University of Khartoum. Trans R Soc Trop Med Hyg. 106(11):639–44. doi: 10.1016/j.trstmh.2012.
07.003 PMID: 22854685
Medicinal Plants Antifungal Activity againstMadurella mycetomatis
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003488 March 13, 2015 7 / 9
13. Mahgoub ES, Gumaa SA. (1984) Ketoconazole in the treatment of eumycetoma due to Madurella
mycetomi. Trans R Soc Trop Med Hyg 78:376–79. PMID: 6087513
14. Fahal AH, Rahman IA, El-Hassan AM, EL Rahman ME, Zijlstra EE. (2011) The efficacy of itraconazole
in the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med
Hyg. 105 (3):127–32. doi: 10.1016/j.trstmh.2010.11.008 PMID: 21247608
15. Wendy Kloezen, Meis Jacques F., Ilse Curfs-Breuker Ahmed Fahal, van de SandeWendyWJ. (2012)
In vitro antifungal activity of isavuconazole to Madurella mycetomatis. Antimicrob Agents Chemother.
56(11):6054–6. doi: 10.1128/AAC.01170-12 PMID: 22964246
16. Ahmed AO, van de SandeWW, van VianenW, van Belkum A, Fahal AH, et nal. (2004). In vitro suscep-
tibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS
method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-
tetrazolium hydroxide (XTT) assay. Antimicrob Agents Chemother 48(7):2742–6. PMID: 15215141
17. van Belkum A, Fahal HA, Wendy van de SandeWW. (2011) In Vitro Susceptibility of Madurella Myceto-
matis to Posaconazole and Terbinafine. Antimicrob Agents Chemother. 55(4):1771–3. doi: 10.1128/
AAC.01045-10 PMID: 21263050
18. van de SandeWW, Fahal AH, Riley TV, Verbrugh H, van Belkum A. (2007). In vitro susceptibility of
Madurella mycetomatis, prime agent of Madura foot, to tea tree oil and artemisinin. J Antimicrob Che-
mother. 59(3):553–5. PMID: 17324961
19. van de SandeWW, de Kat J, Coppens J, Ahmed AO, Fahal A, et al. (2007) Melanin biosynthesis in
Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes In-
fect. 9: 1114–1123. PMID: 17644456
20. Ibrahim AI, El Hassan AM, Fahal A, van de SandeWW. (2013) A histopathological exploration of the
Madurella mycetomatis grain. PLoS One. 8(3):e57774. Epub 2013 Mar 6. doi: 10.1371/journal.pone.
0057774 PMID: 23483927
21. Ezaldeen EA, Fahal AH, Osman A. (2013) Mycetoma Herbal Treatment: The Mycetoma Research
Centre, Sudan Experience. PLoS Negl Trop Dis 7(8): e2400. doi: 10.1371/journal.pntd.0002400 PMID:
23991244
22. National Committee for Clinical Laboratory Standards, Reference method for broth dilution antifungal
susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical
Laboratory Standards, Wayne, Pa (2002).
23. Raaman N. (2006) Phytochemical Techniques. New India Publishing Agency, Chapter six, pp. 40–67.
doi: 10.1016/j.nepr.2005.06.003 PMID: 19040854
24. Banso A. (2009) Phytochemical and antibacterial investigation of bark extract of Acacia nubica. J. Med.
Plants Res 3 (2):082–085.
25. Hammer KA, Carson CF, Riley TV. (2003) Antifungal activity of the components of Melaleuca alternifo-
lia (tea tree) oil. J Appl Microbiol. 95: 853–60. PMID: 12969301
26. Camarda L, Dayton T, Di Stefano V, Pitonzo R, Schillaci D. (2007) Chemical composition and antimi-
crobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae). Annali di Chi-
mica, 9(97), 837–844. PMID: 17970299
27. Abdoul-latif FM, Louis-Clément O, Imael HN, Dicko MH. (2012) Antimicrobial activities of essential oil
and methanol extract of Boswellia sacra Flueck. and Boswellia papyrifera (Del.) Hochst from Djibouti.
Int J Mment, Mod Sc Technol 1(1): 1–10.
28. Wesenberg-Ward KE, Tyler BJ, Sears JT. (2005) Adhesion and biofilm formation of Candida albicans
on native and Pluronic-treated polystyrene. Biofilms, 1(2), Biofilms 63–71. Doi: 10.1017/
S1479050505001687
29. Schillaci D, Arizza V, Dayton T, Camarda L, Di Stefano V. (2008) In vitro anti-biofilm activity of Boswellia
spp. oleogum resin essential oils, Letters in Applied Microbiology 5(47): 433–438. doi: 10.1111/j.1472-
765X.2008.02469.x PMID: 19146534
30. Al-Fattani MA, Douglas LJ (2006) Biofilm matrix of Candida albicans and Candida tropicalis: chemical
composition and role in drug resistance. J Med Microbiol 55(8):999–1008.
31. Hostanska K, DaumG, Saller R (2002) Cytostatic and apoptosis-inducing activity of boswellic acids to-
ward malignant cell lines in vitro. Anticancer Res 22:2853–2862. PMID: 12530009
32. Ammon HP, Safayi H, Mack T, Sabieraj J. (1993) Mechanism of anti-inflammatory actions of curcumine
and boswellic acids. J Ethnopharmacol 38 (2–3): 113–9. PMID: 8099636
33. Fahal AH, El Toum E, El Hassan AM, Mahgoub ES, Gumaa SA. (1995) The host tissue reaction to
Madurella mycetomatis: new classification. J Med Vet Mycol 33(5): 15–17. PMID: 8544084
34. Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, et al. (2006) Mechanisms underlying
the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol 290
(6):1131–7. doi:10.1152/ajpgi.00562
Medicinal Plants Antifungal Activity againstMadurella mycetomatis
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003488 March 13, 2015 8 / 9
35. Sharma A, Bhatia S, Kharya MD, Gajbhiye V, Ganesh N, et.al. (2010) Anti-inflammatory and analgesic
activity of different fractions of Boswellia serrata. Int J Phytomed 1(2): 94–99.
36. Liu M, Chen P, Büchele B, Dong S, Huang D, et al. (2013) A boswellic acid-containing extract attenu-
ates hepatic granuloma in C57BL/6 mice infected with Schistosoma japonicum. Parasitol Res 112
(3):1105–11. doi: 10.1007/s00436–012 PMID: 23271565
37. Devi PR, Adilaxmamma K, Rao GS, Srilatha Ch, Raj MA (2012) Safety Evaluation of Alcoholic Extract
of Boswellia ovalifoliolata Stem-bark in Rats. Toxicol Int 19(2):115–20. doi: 10.4103/0971-6580.97198
PMID: 22778507
38. Ahmed M, Al-Daghri N, Alokail MS, Hussain T (2013) Potential changes in rat spermatogenesis and
sperm parameters after inhalation of Boswellia papyrifera and Boswellia carterii incense. Int J Environ
Res Public Health 10(3):830. doi: 10.3390/ijerph10030830 PMID: 23449005
39. Mahmoudi A, Hosseini-Sharifabad A, Monsef-Esfahani HR, Yazdinejad AR, Khanavi M, et al. (2011)
Evaluation of systemic administration of Boswellia papyrifera extracts on spatial memory retention in
male rats. J Nat Med 65(3–4):519–25. doi: 10.1007/s11418-011-0523-0 PMID: 21479861
40. Singh P, Chacko KM, Aggarwal ML, Bhat B, Khandal RK, et al. (2012. A-90 Day Gavage Safety As-
sessment of Boswellia serrata in Rats. Toxicol Int 19(3):273–8. doi: 10.4103/0971-6580.103668 PMID:
23293466
Medicinal Plants Antifungal Activity againstMadurella mycetomatis
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003488 March 13, 2015 9 / 9
